Skip to main content
logo
Travere Therapeutics, Inc. (TVTX)
NASDAQ: TVTX · Real-Time Price · USD
50.85
+1.25 (2.52%)
Oct 19, 2026, 10:24 AM EDT - Market open

Travere Therapeutics Financials Overview

Millions USD. Fiscal year is Jan - Dec.

Revenue & Profits
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Revenue
591.33490.73233.18145.24109.46131.84
Revenue Growth
77.12%110.45%60.55%32.69%-16.97%-33.52%
Gross Profit
350.12274.387.94-111.2-122.29-73.14
Operating Income
-40.46-62.82-256.18-376.74-319.81-199.43
Net Income
-43.46-25.55-321.55-111.4-278.48-180.09
Earnings Per Share
-0.48-0.29-4.08-1.50-4.37-3.01
EPS Growth
------

Cash & Debt
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Cash & Investments
489.18322.8370.7566.85450.25552.88
Total Debt
616.91328.73401.58404.78407.49261.99
Net Cash (Debt)
-127.73-5.94-30.88162.0742.76290.9
Net Cash Growth
---279.04%-85.30%147.45%
Net Cash Per Share
-1.40-0.07-0.392.180.674.86

Cash Flow & CapEx
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Cash Flow
92.737.78-237.48-280.02-186.29-14.79
Capital Expenditures
------5.1
Free Cash Flow
92.737.78-237.48-280.02-186.29-19.89
Free Cash Flow Growth
------

Margins
Chart
Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Gross Margin
59.21%55.91%3.40%-76.57%-111.72%-55.48%
Operating Margin
-6.84%-12.80%-109.87%-259.40%-292.17%-151.27%
Pretax Margin
-11.34%-10.04%-137.45%-258.96%-302.54%-164.51%
Profit Margin
-7.35%-5.21%-137.90%-76.70%-254.41%-136.60%
FCF Margin
15.68%7.70%-101.84%-192.80%-170.19%-15.09%

Valuation
Chart
Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period EndingOct '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Forward PE
12.8438.0842.8542.8542.8542.85
P/FCF Ratio
50.4490.48----
PS Ratio
7.916.976.504.6512.3314.42